Ferrari and Fox state that 'a better understanding of the interaction between elevated heart rate and left ventricular function helps interpret the results of SIGNIFY'.
Ferrari and Fox state that 'a better understanding of the interaction between elevated heart rate and left ventricular function helps interpret the results of SIGNIFY'. 1 I contend that it is actually the interaction between ivabradine and the aetiology of left ventricular systolic dysfunction (LVSD) which is important. It is really this interaction that helps us understand the apparently conflicting results of BEAUTIFUL, SHIFT, and SIGNIFY. 2 -4 Scrutiny of these three large placebo-controlled randomized trials with ivabradine (Table 1) shows that the two key features were: (i) the entry requirement for documented coronary artery disease (CAD) in two 2, 4 and (ii) the entry requirement for a low left ventricular ejection fraction (LVEF) in two. 2, 3 In addition, symptomatic heart failure (HF) was a necessary inclusion criterion for one trial 2 and an exclusion criterion in another. 4 As a result, there are two trials in which all patients had a low LVEF, with or without symptomatic HF (BEAU-TIFUL and SHIFT), 2, 3 and two trials where all patients had CAD (BEAUTIFUL and SIGNIFY). 2, 4 It is actually the difference in the results between BEAUTIFUL and SHIFT that is most puzzling and concerning, rather than the findings of SIGNIFY. The patients in BEAUTIFUL and SHIFT overlap very closely in most respects, except the aetiology of LVSD. Approximately onethird of the patients with heart failure and a reduced ejection fraction (HF-REF) in SHIFT were said by the investigators to have a nonischaemic aetiology. 3 Therefore, it follows that the strikingly different outcomes in BEAUTIFUL (in which all patients had CAD) and SHIFT ( Table 2 ) might reflect whether or not patients had an ischaemic cause for their LVSD. For that hypothesis to be plausible, three other conditions need to be met. First, the trials must have reported the same outcomes (so the trials can be compared properly) and in sufficient numbers (to have the power to detect a treatment effect, if present). As can be seen from Table 2 , these conditions are fulfilled for BEAUTIFUL and SHIFT. Secondly, ivabradine should lead to little or no improvement in outcomes in any other population defined by the presence of CAD but by the absence of LVSD (so as to allow dissection of any effect of ivabradine on CAD from its effect on LVSD). It is in this respect that SIGNIFY is important. Thirdly and most importantly, in patients with a low LVEF, ivabradine should only be effective (or be more effective) in those without CAD.
Here the results of SHIFT are supportive. In the sub-group analysis according to investigator designated aetiology of HF-REF, the placebo: ivabradine hazard ratio for the primary composite outcome in patients with non-ischaemic HF was 0.72 (95% CI 0.60 -0.85) compared with 0.87 (0.78-0.97) in those with an ischaemic aetiology. 3 The important point about this analysis is that the interaction P-value was 0.059. The test for interaction is statistically weak and some authorities argue that a larger P-value, e.g. ,0.1 should be considered as possibly indicative of a true interaction. 5 Of course, there are several limitations to this analysis. First, without coronary angiography, investigator-reported aetiology is unreliable. Secondly, sub-group analysis itself is unreliable and prone to giving false findings as a result of the play of chance. 5 On the other hand, digoxin which slows heart rate and reduces the risk of HF hospitalization by a similar magnitude to ivabradine also has a somewhat larger treatment effect in patients with non-ischaemic HF-REF. 6 The placebo: digoxin hazard ratio for the composite outcome of HF death or HF hospitalization in patients with non-ischaemic HF was 0.67 (95% CI 0.58-0.77) compared with 0.79 (0.72-0.88) in those with an ischaemic aetiology in the Digitalis Investigators Group trial. 7 The reader is also referred back to Table 2 . Given the substantial relative risk reduction of 26% in HF hospitalization in SHIFT, how else can the complete lack of effect on exactly the same outcome in very alike patients in BEAUTIFUL be explained? The number of patients with such an event was large (over 850), all had LVSD and the average dose of ivabradine taken in both trials was similar. While the reduction in heart rate was less in BEAUTIFUL (because the starting heart rate was lower) than in SHIFT, a sub-group analysis of patients with a heart rate of ≥70 bpm at baseline in BEAUTIFUL (among whom the placebo-corrected fall in heart rate at 6 months was 9.0 bpm) also showed no effect of ivabradine on the composite of cardiovascular death or HF hospitalization or its components. Consequently, it is hard to argue from these data
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that it is background LVEF, dose of drug or effect of treatment on heart rate that explains the difference between BEAUTIFUL (which was neutral) and SHIFT (which was positive for a reduction in HF hospitalization). Why should ivabradine have more effect in patients with nonischaemic HF-REF than in those with ischaemic HF-REF? This differential effect has been suggested not only for digoxin (as mentioned above) but also for b-blockers, amiodarone, and cardiac resynchronization therapy, in at least some studies. 8, 9 One hypothesis is that ischaemic LVSD is characterized by loss of substantial quantities of myocardium through infarction and leads to irreversible scarring and limited potential for recovery whereas some or much of non-ischaemic left ventricular systolic dysfunction may be reversible. Interestingly, in SHIFT the ivabradine-associated reduction (improvement) in left ventricular systolic volume index was smaller (25.51 mL/m 2 ) in patients with an ischaemic aetiology compared with those with a non-ischaemic aetiology (27.61 mL/m 2 ). 10 Another possibility is that differential metabolic remodelling in ischaemic and non-ischaemic HF might result in a differential response to treatment.
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Although I do not agree with Ferrari and Fox about their interpretation of BEAUTIFUL and SHIFT, I do agree with them that all three trials tell us that ivabradine does not improve CAD outcomes. In this respect, their Figure 1 is misleading by comparing different types of outcomes in the trials illustrated. Instead, it is better to look at the rate of hospitalization for myocardial infarction which is a hard CAD endpoint and which was reported in both BEAUTIFUL and SIGNIFY. This endpoint was not reduced significantly in either trial. Indeed, we do not have convincing data that any 'anti-anginal' drug improves hard outcomes in patients with CAD, although nicorandil reduces hospitalization for cardiac chest pain. 12 The exception is b-blockers which reduce risk of death and recurrent infraction after acute myocardial infarction. More relevant to the current discussion, carvedilol reduces both the risk of death and re-infarction in patients with recent myocardial infarction, LVSD, and a heart rate ≥60 bpm, as demonstrated in the Carvedilol Post-Infarct Survival Control in LV Dysfunction trial (CAPRICORN). 13 The findings of CAPRICORN stand in striking contrast to BEAUTIFUL.
